Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
Go back to Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program| (NYSE: ATH) | Delayed: 83.33 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $83.33 | 52 Week High | $ | |||
| Open | $83.33 | 52 Week Low | $ | |||
| Day High | $83.33 | P/E | N/A | |||
| Day Low | $83.33 | EPS | $ | |||
| Volume | 7,858 | |||||
| (NASDAQ: ATHE) | Delayed: 4.17 +0.02 (0.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.15 | 52 Week High | $ | |||
| Open | $4.05 | 52 Week Low | $ | |||
| Day High | $4.26 | P/E | N/A | |||
| Day Low | $3.98 | EPS | $ | |||
| Volume | 32,608 | |||||
